Last reviewed · How we verify
NCT06680739: SERPENTINE
Single cEll pRofiling PErsistaNce To ImmuNothErapy
Phase 2 trial testing Durvalumab in Colorectal Cancer in 60 participants. Currently enrolling.
1 September 2025
Quick facts
| Lead sponsor | Vall d'Hebron Institute of Oncology |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 March 2022 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Durvalumab — full drug profile →
- Tremelimumab (TREMELIMUMAB) — full drug profile →
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Endometrial Cancer — all drugs for Endometrial Cancer →
Sponsor
Vall d'Hebron Institute of Oncology
Who can join
18 and older, any sex, with Colorectal Cancer or Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The SERPENTINE trial (ESR 21-21165) is a phase II clinical study aiming to evaluate the efficacy of durvalumab and tremelimumab, alone or in combination, in patients with colorectal or endometrial cancer. The trial targets patients with microsatellite instability-high (MSI-H) tumors and those with microsatellite stable (MSS) tumors. Colorectal and endometrial cancers present significant challenges due to their heterogeneity and variable responses to treatment. Immunotherapy, particularly checkpoint inhibitors like durvalumab and tremelimumab, has shown promise in some patients, but predicting response remains elusive. The SERPENTINE trial aims to address this gap by investigating the effectiveness of these immunotherapies in a carefully selected patient population.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immunotherapy in endometrial cancer: mechanisms, clinical evidence, and future directions.
Lian M, Zhang C, Li T, Wang A. · · 2025 · cited 1× · PMID 41583426 · DOI 10.3389/fimmu.2025.1697065 -
Predictive biomarkers of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer.
Grau Béjar JF, Yaniz Galende E, Genestie C, Blanc-Durand F, et al · · 2026 · PMID 41835337 · DOI 10.1177/17588359261423888
Verify or expand the search:
- PubMed search for NCT06680739
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Durvalumab
Trials testing the same drug.
- NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
- NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
- NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
- NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Vall d'Hebron Institute of Oncology trials
Trials by the same sponsor.
- NCT06411600 — Combination Therapy for BRAF-V600E Metastatic CRCm · Phase 2 · recruiting
- NCT05385705 — A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refracto · Phase 1 · terminated
- NCT05141474 — Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte ( · EARLY_PHASE1 · recruiting
- NCT05534178 — Machine Learning Model to Predict HOLS and Mortality After Discharge in Hospitalized Oncologic Patients · unknown
- NCT03979131 — Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06680739 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vall d'Hebron Institute of Oncology
- Last refreshed: 8 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06680739.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing